TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer

被引:0
|
作者
Ralf Erber
Christian Conradt
Nils Homann
Christel Enders
Martin Finckh
Andreas Dietz
Hagen Weidauer
Franz X Bosch
机构
[1] Molekularbiologisches Labor,
[2] Hals-Nasen-Ohren-Klinik,undefined
[3] Universität Heidelberg,undefined
[4] Institut für Medizinische Biometrie,undefined
[5] Universität Heidelberg,undefined
[6] Hals-Nasen-Ohren-Klinik,undefined
来源
Oncogene | 1998年 / 16卷
关键词
TP53; mutation types; clinical course; head and neck cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties. We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact. Thirty-seven missense mutations were identified. Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 β strand and in Zinc binding residues. Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed). In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test). The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test). These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate wild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.
引用
收藏
页码:1671 / 1679
页数:8
相关论文
共 50 条
  • [21] TP53 mutations are associated with a particular pattern of genomic imbalances in head and neck squamous cell carcinoma
    Smeets, S.
    Braakhuis, B.
    Leemans, C. R.
    Brakenhoff, R.
    ORAL ONCOLOGY, 2007, : 196 - 196
  • [22] TP53 gene mutations in plasma DNA of cancer patients
    Silva, JM
    Gonzalez, R
    Dominguez, G
    Garcia, JM
    España, P
    Bonilla, F
    GENES CHROMOSOMES & CANCER, 1999, 24 (02): : 160 - 161
  • [23] Impact of TP53 mutations in Triple Negative Breast Cancer
    Zahi I. Mitri
    Nour Abuhadra
    Shaun M. Goodyear
    Evthokia A. Hobbs
    Andy Kaempf
    Alastair M. Thompson
    Stacy L. Moulder
    npj Precision Oncology, 6
  • [24] Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer
    Netter, Jeanne
    Lehmann-Che, Jacqueline
    Lambert, Jerome
    Tallet, Anne
    Lourenco, Nelson
    Soliman, Hany
    Bertheau, Philippe
    Pariente, Benjamin
    Chirica, Mircea
    Pocard, Marc
    Allez, Matthieu
    De The, Hugues
    Gornet, Jean-Marc
    BULLETIN DU CANCER, 2015, 102 (02) : 117 - 125
  • [25] Impact of TP53 mutations in Triple Negative Breast Cancer
    Mitri, Zahi, I
    Abuhadra, Nour
    Goodyear, Shaun M.
    Hobbs, Evthokia A.
    Kaempf, Andy
    Thompson, Alastair M.
    Moulder, Stacy L.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [26] Clinical implications of germline mutations in breast cancer: TP53
    Katherine Schon
    Marc Tischkowitz
    Breast Cancer Research and Treatment, 2018, 167 : 417 - 423
  • [27] Clinical implications of germline mutations in breast cancer: TP53
    Schon, Katherine
    Tischkowitz, Marc
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 417 - 423
  • [28] Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer
    Sheng, Shuyan
    Xu, Ye
    Guo, Yonghai
    Yao, Lu
    Hu, Li
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (02) : 487 - 495
  • [29] A prognostic model of head and neck cancer ties TP53 mutation to 3p loss
    Gross, Andrew M.
    Orosco, Ryan K.
    Shen, John P.
    Egloff, Ann Marie
    Carter, Hannah
    Hoffree, Matan
    Choueiri, Michel
    Coffey, Charles S.
    Lippman, Scott M.
    Hayes, David Neil
    Cohen, Ezra E.
    Grandis, Jennifer R.
    Nguyen, Quyen T.
    Ideker, Trey
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
    Gu, Yun
    Sun, Mengyao
    Fang, Hanji
    Shao, Fei
    Lin, Chao
    Liu, Hao
    Li, He
    He, Hongyong
    Li, Ruochen
    Wang, Jieti
    Zhang, Heng
    Xu, Jiejie
    BRITISH JOURNAL OF CANCER, 2024, : 1320 - 1327